FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.
D000079963:Brentuximab Vedotin; D017277:Drug Approval; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D018796:Immunoconjugates; D000079963:Brentuximab Vedotin